Antibody-secreting cells (ASCs) represent the main effector B cells in protective responses and in pathogenic conditions that include autoimmunity, allergy and transplantation. ASCs are released in large numbers into the circulation during recall vaccine responses, which induce a transient 10-to 40-fold increase in ASCs after immunization 1 . Single-cell studies have shown that those ASCs are vaccine specific, oligoclonal and highly mutated, suggestive of derivation from pre-existing memory cells 2 .
Antibody-secreting cells (ASCs) represent the main effector B cells in protective responses and in pathogenic conditions that include autoimmunity, allergy and transplantation. ASCs are released in large numbers into the circulation during recall vaccine responses, which induce a transient 10-to 40-fold increase in ASCs after immunization 1 . Single-cell studies have shown that those ASCs are vaccine specific, oligoclonal and highly mutated, suggestive of derivation from pre-existing memory cells 2 .
ASC population expansions of even larger magnitude are typical of acute systemic lupus erythematosus (SLE) 3 . SLE is a relapsing autoimmune disease characterized by high titers of serum autoantibodies, some of which (antibody to double-stranded DNA (anti-dsDNA) and 9G4 antibodies encoded by the immunoglobulin variable heavy-chain gene segment V H 4-34) fluctuate with disease activity 4, 5 . Given the availability of autoantigens and the abundance of memory cells in SLE, increased numbers of ASCs coincident with disease flares might be expected to represent oligoclonal expansions of pre-existing memory cells specific for lupus antigens. However, the properties of ASCs and their contribution to serum autoantibodies during SLE flares remain uncertain.
We addressed the questions posed above through simultaneous analysis of sorted B cells and ASCs from patients with SLE experiencing disease-associated flares. We elucidated repertoire properties and population inter-relatedness by next-generation sequencing (NGS) and analyzed the autoantibody compartment by proteomic profiling of serum samples ('serum proteomics') and with single-cell monoclonal antibodies. Our results demonstrated that circulating ASCs present during SLE flares were highly polyclonal and did not recognize predominantly the most prevalent lupus antigens. However, this polyclonal repertoire was punctuated by the expansion of complex clones expressing mainly disease-specific V H 4-34-encoded autoantibodies. A distinct subset of activated naive B cells (acN cells) was an important source of ASCs and serum autoantibodies during SLE flares. This subset expressed highly reactive, germline-encoded autoantibodies and persisted in the circulating pool for prolonged periods of time, together with their ASC progeny. Our results shed light on the mechanisms of B cell hyperactivity in SLE and might be used to distinguish patients' disease-activity levels and guide therapeutic options.
RESULTS

Polyclonality of circulating ASCs during SLE flares
We obtained peripheral blood ASCs from patients with SLE who were experiencing disease flares while on minimal immunosuppression (Supplementary Table 1 ). Consistent with published observations 3 , ASCs defined as CD19 + IgD − CD27 hi CD38 hi were up to 40-fold more abundant in these patients than in healthy subjects (Fig. 1a) 7 5 6 VOLUME 16 NUMBER 7 JULY 2015 nature immunology A r t i c l e s and included Ki67 + CD138 − and Ki67 + CD138 + subsets (Fig. 1b) . Thus, all circulating ASCs in SLE represented proliferative plasmablasts in various stages of maturation.
We sorted both of those ASC subsets, as well as naive cells (CD19 + IgD + CD27 − ) and IgD − memory cells (CD19 + IgD − CD27 + , including isotype-switched and immunoglobulin M (IgM)-only cells), and sequenced their rearranged genes encoding antibody heavy chains. We first analyzed NGS data for clonal diversity. As in published studies of vaccination against influenza virus 6 and multiple sclerosis 7, 8 , we assigned sequences to individual clones (clonotypes) if they shared rearrangements of V H and joining heavy-chain (J H ) segments, an identical length of immunoglobulin heavy-chain complementarity-determining region 3 (HCDR3) and a Hamming identity of >85% for HCDR3 (Supplementary Note 1). Increasing the HCDR3 similarity to >90% did not substantially alter clonal assignments (data not shown). Therefore, we chose to use a threshold of >85% for the Hamming identity to allow a frequency of HCDR3 mutation in ASCs relative to that in their naive precursors similar to the mutation frequency present in HCDR1 and HCDR2 expressed by ASCs in published studies of responses to influenza virus 6 and in our own data set (Supplementary Note 1 and Supplementary Figs. 1-3) .
Given the scarcity of data available on the normative distribution of clonal size at steady state and during active immune responses 6, 9 , adjudication of abnormal clonotype expansion is necessarily arbitrary. Accordingly, we used several metrics to consistently measure clonal size, the contribution of large clones and repertoire diversity. The metrics assessed included the contribution by any clone to the total number of sequences (Fig. 1c) and the number of the largest clonotypes that accounted for 20% (D 20 ) or 50% (D 50 ) of all sequences (Supplementary Table 1 ). In addition, we classified many of the largest clones as having expanded substantially (Fig. 1d) . In this context, 'expanded lineages' is a heuristic for the number of unusually large clones within a population, defined as the number of size-ordered lineages after the first occurrence of a change ('delta') of 0.1% between adjacent clone sizes. We analyzed samples before and after the removal of redundant sequences and observed a minimal change in clonal size relative to total size (data not shown).
ASCs from patients with SLE expressed a very polyclonal repertoire in which abnormally expanded clones represented a much smaller fraction of the total compartment and were substantially smaller than those from healthy control subjects either vaccinated with tetanus toxin or vaccinated against influenza virus (Fig. 1c,d , Supplementary  Fig. 4 Table 1 ). The frequency of sequences that made up expanded CD138 + ASC clones, defined as meeting a difference threshold of 0.1% larger the previous clone in the size-ranked clones, was much lower in patients with SLE than in vaccinated healthy control subjects (Fig. 1c,d and Supplementary Table 1) . Nonetheless, ASC populations from patients with SLE included a small number of sizable clonal expansions (2-10 and 0-18 expanded clonotypes in CD138 − ASCs and CD138 + ASCs, respectively; Fig. 1d ). This pattern was most prominent in patients SLE-2 and SLE-4. Thus, the D 20 values for CD138 + ASCs from patients SLE-2 and SLE-4 were only 26 and 31, respectively, with the largest clone in SLE-4 accounting for over 6% of 5 × 10 4 unique sequences obtained from 2 × 10 5 cells (Fig. 1d) . In patient SLE-2, the largest clone accounted for 2.1% and 1.5% of all sequences identified from CD138 − ASCs and CD138 + ASCs, respectively (Fig. 1d) present in the total naive compartment of patient SLE-2, possibly due to the presence of an activated fraction of cells in the total naive compartment (Supplementary Table 1 and Supplementary Fig. 5 ). This patient, who was on minimal immunosuppression, experienced a major acute flare accompanied nephritis and central nervous system, hematological and serological manifestations. Similarly, memory cells were highly polyclonal in the group vaccinated against influenza virus and in the group with SLE, but striking clonal expansions were displayed after vaccination of healthy control subjects with tetanus toxin (Supplementary Table 1 and Supplementary Fig. 5 ). Clonal sizes calculated from sequence numbers could be influenced by mRNA abundance per cell and PCR-induced skewing. However, mRNA abundance should be similar within purified cell subpopulations. A notable exception could apply to populations that might contain a fraction of highly activated B cells with possibly higher expression of mRNA from the immunoglobulin heavy-chain locus (IGH). In this case, the estimated clonal size would be immunologically informative by identifying such population. Finally, we assumed that PCR skewing for any given V H segment should affect all subpopulations and clinical samples equally.
As expected, IgG and IgA isotypes represented the majority of sequences in ASCs (Fig. 2a) . IgM provided a sizable contribution (5.42-19 .53%) of all sequences in ASCs from patients with SLE, with substantial inter-subject variability in the contribution from IgM observed among vaccinated healthy control subjects (Fig. 2a) . Of note, the frequency of IgM sequences in the IgD − CD27 + memory cell population was significantly greater for patients with SLE than for healthy control subjects after vaccination (20.9-68.1% and 1.5-37.5%, respectively; Fig. 2a ). These numbers were consistent with the frequency of IgM + memory cells observed by flow cytometry in 120 patients with SLE (median of 9.1%, with an upper limit of 60.6%; data not shown). In summary, ASCs from patients with SLE undergoing flares were highly polyclonal and contained, in addition to classswitched sequences, a substantial fraction of IgM sequences that presumably were derived from recently activated naive cells, as has also been seen after repeated vaccination with the human immunodeficiency virus gp120 vaccine 10 and/or in IgM + memory cells 11 .
Lower frequency of somatic hypermutation in SLE ASCs
We calculated the frequency of somatic hypermutation (SHM) by determining the length of the corresponding germline V H region in each sequence (approximately 285 base pairs (bp), although this varies by V H segment) and ascertaining the frequency of mutations in non-gap bases within that V H segment. ASCs from patients with SLE displayed a lower average mutation rate (4.98%) than that of ASCs from vaccinated healthy control subjects (7.33%) (Fig. 2b) . Notably, samples from patients with SLE contained a large fraction of cells with less mutation, with 32.5% of sequences from CD138 − ASCs and 30.8% of sequences from CD138 + ASCs containing fewer than 3% mutations (8.55 mutations per sequence, based on a germline V H segment of 285 bp), compared with 11.8% of sequences from CD138 − ASCs and 10.0% of sequences from CD138 − ASCs in samples from vaccinated healthy control subjects (Fig. 2b) . Patients SLE-4 and SLE-5 had a particularly large number of sequences in ASCs with less mutation (39.8 and 52.9%, respectively) (Fig. 2b) . We confirmed these results by single-cell analysis of 771 isotype-switched ASCs mutations (%) obtained from six additional patients with SLE. In this cell population, 4% of the V H sequences were not mutated, and sequences with less mutation averaged 18.5%, with a range of 7.1-38.5% among individual patients (data not shown). The median mutation frequency was substantially higher in the hypervariable CDR than in framework regions (FRs) (an average of 6.74% (CDR) and 3.15% (FR), for patients with SLE, and 12.35% (CDR) and 4.57% (FR), for vaccinated healthy control subjects; Fig. 2c ). The ratio of replacement mutations to silent mutations was also higher in the CDR: 5.83 replacement versus 0.00 silent (CDR), and 1.49 replacement versus 0.70 silent (FR), for patients with SLE; consistent with reference values for influenza virus-selected ASCs 6 and the results obtained for healthy control subjects after vaccination (9.52 replacement versus 0.42 silent (CDR), and 2.92 replacement versus 1.49 silent (FR)). Thus, the pattern obtained for patients with SLE was consistent with antigen-driven selection of the precursors of ASCs, as expected for pre-existing memory cells and newly recruited naive cells driven through stimulation via the B cell antigen receptor (BCR).
SLE ASCs are punctuated by complex V H 4-34 + clonal expansion
We analyzed the use of IGH V H segments to understand repertoire complexity. Of the 42-46 functional germline V H segments available, V H 4-34 accounted for 5.9-19.5% of all sequences in ASCs from patients with SLE, but it accounted for a significantly lower fraction in vaccine responses (1.1-7.6% and 1.6-11.1% for vaccination against influenza virus and the tetanus toxin vaccine, respectively; Fig. 3a ). In the top 20% of sequences (the D 20 fraction), this contrast was even more apparent, with CD138 − ASCs from patients with SLE containing an average of 20.7% V H 4-34 sequences, compared with 2.9% in the samples from healthy control subjects after vaccination. Similarly, V H 4-34 contributed an average of 19.8% of the D 20 fraction of sequences in CD138 + ASCs from patients with SLE but only 5.3% in the samples from healthy control subjects after vaccination. This highly autoreactive V H segment has been found to correlate with active SLE in serological studies 4, 5 , and in our studies it accounted for 21% of the largest ten ASC clones in patients with SLE and contributed substantially to clonal expansion in all five patients. In contrast, V H 4-34 contributed to ASC population expansion in only two of eight vaccinated healthy control subjects. Conversely, other V H segments commonly expressed in the human antibody repertoire (V H 3-23 and V H 1-69) and overexpressed during infection with influenza virus, human immunodeficiency virus or hepatitis C virus (V H 1-69) 12 contributed significantly to ASCs from healthy control subjects responding to vaccination but much less prominently to ASCs from patients with SLE. Moreover, V H 4-34 was not common in ASC populations expanded during the active phase of other antibody-mediated autoimmune diseases, including pemphigus vulgaris and IgG4-related disease. Thus, these findings ruled out the possibility of technical skewing and, in keeping with the high specificity for SLE of 9G4 antibodies 5 , demonstrated 'preferential' population expansion of V H 4-34 + ASCs from patients with SLE undergoing flares.
SLE flares course with generalized ASC population expansion
We analyzed samples from a larger number of patients with SLE by enzyme-linked immunospot (ELISPOT) assay to determine autoreactive and anti-microbial responses. We assessed autoreactivity to common SLE antigens, including dsDNA, Ro and Smith. We also assessed V H 4-34-encoded 9G4 antibodies, which contribute substantially to dsDNA responses and capture additional SLE autoreactivity, including antibodies to apoptotic cells 13, 14 , and thereby provide a more encompassing measure of lupus autoreactivity. Despite the absence of recent immunization or likely natural exposure, cells specific for influenza virus or tetanus toxin were much more frequent among ASCs from patients with SLE (range, 0-1.2% or 0-0.65%, respectively, of all IgG + ASCs) than their undetectable frequency among ASCs from healthy control subjects (Fig. 3b) . In contrast, even in patients with large expansions of ASC populations, anti-dsDNA, anti-Ro and antiSmith responses common to SLE together accounted for less than 3% of IgG-producing ASCs (Fig. 3c) . Of note, these frequencies closely matched similar autoimmune responses in a mouse model of lupus 15 .
The median frequency of 9G4 + ASCs was 2.4% and, consistent with published results 16 , could account for up to 20% of all IgG + ASCs. Thus, circulating ASCs from patients with SLE had enhanced responses to infectious antigens as well as autoantibodies typical of SLE. The latter, however, accounted for only a limited fraction of all ASCs and, in keeping with the NGS data, were dominated by 9G4 antibodies.
Contribution of naive cells to ASCs in SLE flares
ASCs originate either from pre-existing memory B cells or from newly acN cells through germinal center (GC) or extrafollicular reactions 11 , with both pathways having a prominent role in mouse models of lupus [17] [18] [19] . To determine the contribution of naive cells to ASC population expansion in SLE, we analyzed the NGS data for connectivity using the 85% clonal-identification-metric method (Supplementary Note 1). We quantified results using a correction score to account for the variability introduced by differences in the number of input cells in separate subjects as well as sequences available. Patients with SLE displayed a significantly higher degree of naive cell-to-ASC connectivity than did vaccinated control subjects (Fig. 4a,b) . Thus, the average ratio of the connections between IgD − memory cells and ASCs to the connections between naive cells and ASCs was significantly lower in SLE than in recall responses elicited by the vaccination of healthy subjects (Fig. 4c) . Notably, naive B cells in the patients with the highest frequency of ASCs with less mutation (SLE-4 and SLE-5) 
contributed approximately 40% and 25%, respectively, of all ASC connectivity (Fig. 4c) . Further illustrating the important contribution of naive cells, we were able to identify the common ancestor for several of the largest ASC clones in naive B cells simultaneously present in the circulation (Fig. 4a,b,d ). We also found in patients with SLE a sizeable contribution of naive cells to ASC populations, including the larger clones, for the predominant V H 4-34 + clones (Fig. 4b) . Thus, we found that naive B cells were vigorously recruited into the enhanced ASC response characteristic of SLE flares. 20 , and by expression of the cell surface marker CD24. In healthy control subjects, the CD19 + IgD + CD27 − population was overwhelmingly dominated by resting naive B cells (Fig. 5) . Patients with SLE had substantial expansion of the MTG + CD24 pos-hi transitional cell population (Fig. 5) , as has been reported in experiments using alternative markers 21 . In addition, flaring SLE was also characterized by large increases in MTG + CD24 − cell populations that were nearly absent from healthy control subjects (Fig. 5a,e) . This population was characterized by a CD19 hi CD21 − CD38 lo IgM lo CD23 − phenotype (Fig. 5a-c) . While an IgD + MTG + phenotype is also shared by late transitional cells 20 , the lack of expression of CD24 and CD38, low expression of IgM and the absence of CD10 militated against this alternative. Instead, we surmise that this subset represented recently acN cells. In support of this interpretation, activated B cells show concomitant upregulation of CD19 expression and downregulation of CD21 expression 22, 23 and positive staining by and/or retention of MTG 20 . This contention was also supported by concordance with disease activity during longitudinal analysis (Fig. 5f) . Of relevance, CD19 hi activated B cell populations showed considerable enrichment for autoreactive 9G4 + B cells (Fig. 5c) , a finding consistent with the prominent contribution of V H 4-34 + naive cells to the clonal expansion of ASCs. in the naive compartment of patients with SLE analyzed longitudinally during periods that included moderate and severe flares in the context of persistent disease activity. *P < 0.0005 and **P < 0.00005 (t-test, unequal variance). Data are representative of 30 experiments with one subject each (a,e; n = 6 samples (healthy control subjects), n = 9 samples (patients with SLE without flare), and n = 15 samples (patients with SLE experiencing an acute flare)), 21 experiments with one subject each (b; n = 6 samples (healthy control subjects) and n = 15 samples (patients with SLE experiencing an acute flare)), 15 experiments with one subject each (c,d; n = 15 samples (patients with SLE experiencing an acute flare)), or 13 experiments (f; n = 13 samples (patients with SLE)).
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From a repertoire standpoint (Fig. 6a) , the salient properties of acN cells were increased clonality (D 20 index 28.7-fold higher than that of naive cells from healthy control subjects) and a high degree of ASC connectivity, with up to 32.5% of all sequences from acN cells and nine of the ten largest acN cell clones representing clonal precursors of ASCs (Fig. 6a,b) . Of note, these measurements varied considerably during longitudinal analyses. This suggested a highly dynamic population and indicated that, as it might be predicted given the necessary lag time between activation of naive cells and clonal expansion of their ASC progeny, the single-time-point analysis substantially underestimated the contribution of newly activated B cells (Fig. 6a) .
Another distinctive feature of acN cells was a substantial frequency of SHM (an average of 2.37% in six samples, compared with only 0.95% for resting naive B cells; data not shown), a process associated with GC cells that can also occur in activated extrafollicular precursors of ASC 17, 24 . The rarity of mutation in resting naive cells indicated that this result could not be explained either by sequencing errors or V H polymorphisms.
To better understand the dynamics of expanded populations of ASCs in lupus and their naive precursors, we constructed their phylogenetic relationships with IgTree software 25 . This tool identified complex clones in which naive cells with no SHM or low degree of SHM (0-2%) co-existed with ASCs with a large 'load' of SHM (mutation frequency of up to 21.5%). As examples, we aligned sequences from large clonotypes that stemmed from an acN cell without mutation and included CD138 + ASCs and CD138 − ASCs that were simultaneously present in the circulation (Fig. 6c,d ). We were able to generate similar trees for 55% of the top 20 connected clones analyzed (data not shown). Given the rate of SHM in antigen-driven mouse autoimmune B cells 26 , these data would be best explained by prolonged persistence and diversification of acN cells in human SLE, as has been proposed in mouse models 24 . This model was supported by the ready identification at the single-cell level, in a patient with SLE, of acN B cells clonally related to mutated ASCs detected by NGS 4 months earlier (Fig. 6e) . Combined, our results indicated that large naive B cell clones persisted and recirculated for several months in patients with SLE.
Contribution of ASC clonal expansion to serum autoantibodies
To confirm the NGS results and establish the functional consequence of ASC population expansion, we obtained affinity-purified serum 9G4 antibodies from one informative sample from a patient with npg A r t i c l e s SLE experiencing an acute flare and characterized the antibodies by liquid chromatography-tandem mass spectrometry 27 . We identified candidate antibodies by mapping high-confidence peptide spectra. We searched mass spectra in the SEQUEST data-analysis program used for protein identification against NGS databases obtained from distinct populations of B cells and ASCs isolated from the same blood sample. We established perfect identity between the full-length heavy-chain protein sequence and NGS sequences for 39 serum 9G4 + antibodies representing 20 distinct clonotypes. Two clonally related serum 9G4 antibodies that shared the same HCDR3 peptide (Fig. 7a) were identical matches with two ASC sequences (Fig. 7b,c) in the largest V H 4-34 + clone found in patient SLE-3. Suggestive of a derivation from naive cells, the protein and corresponding ASC nucleotide sequences were almost completely devoid of any mutation (Fig. 7b) . Consistent with prolonged persistence of ASCs and ongoing antibody production, both the serum 9G4 antibody clonotype and the corresponding ASC clones persisted in the circulation for over 8 weeks (Supplementary Fig. 6 ). Thus, persistent ASC clones directly derived from naive cells contributed substantially to the serum autoantibody repertoire in SLE.
Single-cell analysis of ASC autoreactivity and origin The autoreactivity of 9G4 monoclonal antibodies derived from naive and memory cells from patients with SLE has been documented 13 . 
Figure 7
Serological consequence and cellular derivation of expanded ASC clones in SLE. (a) Proteomic analysis of affinity-purified 9G4 antibodies in serum from patient SLE-3 experiencing an acute flare, treated to proteolytic digestion (above plots) to show spectra of overlapping peptides spanning the HCDR3 sequence ARAPGLDRDYYYYYYMDV. m/z, mass/charge. (b) Alignment of an HCDR3 sequence and two linked V H sequences (separated by a single point mutation) also identified by proteomics, against sequences from ASCs identified by NGS in the same blood sample from the patient in a (additional data of longitudinal serum and ASC samples, Supplementary Fig. 6 ). (c) Phylogenetic analysis (with IgTree software) to localize the ASC origin of the serum antibody in the largest V H 4-34 + clone present in patient SLE-3 at the early flare time point; arrows indicate exact sequences found by proteomic analysis of patient serum. Data are representative of two independent experiments with one subject.
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To establish the applicability of those findings to ASCs, we sorted 9G4 + plasmablasts from a patient with SLE who had been analyzed by NGS 4 months earlier, at the time of an SLE flare. We obtained productively rearranged V H 4-34 sequences and paired light chains from 44 single cells and classified those sequences into 39 separate clonotypes, of which 16 corresponded to clones originally identified by NGS. In all, 36% of the single ASCs analyzed were clonally related to earlier ASC NGS data, with 4.5% representing identical matches (data not shown); this confirmed the proposal of the persistence of ASCs. We then generated recombinant monoclonal antibodies from sequences representative of each clonotype present at the time of flare. The 9G4 antibodies from ASCs displayed substantial autoreactivity, including autoreactivity to antinuclear antibodies (ANA), dsDNA, chromatin, Ro and ribosomal P antigens (Fig. 8a,b) . Some antibodies displayed substantial auto-polyreactivity to dsDNA, chromatin and ribosomal P antigens (Fig. 8a,b) , which are highly specific for SLE 28 . However, these antibodies did not react with influenza virus or tetanus antigens (Fig. 8a) . A highly autoreactive antibody (652 F6) had heavy and light chains without mutation that had complete identity to fourth-largest V H 4-34 + ASC clone at the time of flare (Fig. 8c) . Combined, these data established the direct naive-cell derivation of a highly autoreactive ASC clone that expanded during a lupus flare. This finding also represented evidence of the generation of SLE-specific IgG autoantibodies from germline sequences without the need for SHM or affinity maturation.
DISCUSSION
Understanding the provenance, repertoire and serological consequences of ASC population expansion is essential for delineating the pathogenesis of SLE and for therapeutic insights 29 . We found that these ASCs expressed a highly polyclonal repertoire punctuated by large clonal expansions dominated by autoreactive VH4-34 + cells and shaped the serum autoantibody compartment. This profile was present even in a patient with very acute SLE with major multi-organ involvement.
Our study of SLE has delineated the connectivity among B cell subsets during an ongoing autoimmune response. Indeed, a relevant observation was that the two major subsets of circulating ASCs (CD138 − ASCs and the more mature CD138 + ASCs) were highly interconnected and represented newly produced proliferative plasmablasts in the process of ongoing maturation.
Polyclonal ASCs could indicate activation of bystander B cells 30 or antigen-driven stimulation by multiple lupus autoantigens 28 . Serological studies of human SLE have argued for generalized activation 15 , whereas in mice, antigenic drive has been favored 31 . The NGS data and simultaneous increases in anti-microbial and autoreactive A central finding of our study was that during SLE flares, a substantial contribution to ASC expansion was derived from acN cells that survived for months while still serving as precursors of dynamically diversifying ASCs. Of note, our analysis must have underestimated the participation of naive cells, as the expansion of naive precursor cell populations would occur days to weeks before the generation of ASCs. Moreover, our stringent criteria would have low sensitivity for the detection of clonal relationships between naive cells and mutated ASCs. The relevance of acN cells was emphasized by their temporal relationship with active disease; the high clonality index, suggestive of antigen-driven population expansion; enrichment for autoreactive 9G4 + B cells; and the high frequency of IgD − IgM + memory cells, the first memory 'layer' generated from naive cells in both a GC-dependent fashion and a GC-independent fashion 11 . Enhanced participation by naive cells would also help explain the lower levels of SHM displayed by ASCs from patients with SLE relative to that of memory cells.
Our results provide new insight into the phenotype, magnitude and downstream consequences of the activation of naive B cells in SLE. Indeed, the previously recognized population expansion of CD21 lo activated B cells was ascribed to CD27 + B cells 23 , while other studies did not discriminate among transitional and/or recent immigrant and mature naive B cell subsets 21 , a limitation overcome by incorporation of the analysis of MTG staining and CD24 expression 20, 35 . Also in contrast with published studies, in our experiments, acN cells were CD23 − , a finding consistent with the downregulation of CD23 expression induced by sustained activation of the BCR, Toll-like receptor 9 and interferon-α and interferon-γ [36] [37] [38] , all important stimulatory pathways in SLE 32 .
Population expansion of ASCs during lupus flares might be expected to represent recall responses due to chronic exposure of patients to autoantigens, as has been shown for multiple sclerosis 39, 40 . So how do acN cells in patients with SLE compete with memory cells presumed to have higher responsiveness, affinity and precursor frequency? Such properties remain to be assessed in chronic human autoimmune diseases, particularly in SLE, in which many variables and serum factors may enhance the competitiveness of naive B cells 41 . Thus, naive B cell populations have a high frequency of cells with SLE-related autoreactivity 4, 42 and thus have a greater total number of autoreactive precursor cells than a healthy naive compartment has. Moreover, naive cells not only are able to powerfully generate ASCs through an extrafollicular pathway but might also be very adept at generating GCs 11, 43 .
The autoantigens targeted by ASC oligoclonal expansion during SLE flares remain to be elucidated by large-scale single-cell analysis. Nevertheless, an autoantigen-driven process was suggested by our finding of pronounced clonal expansion of VH4-34 + ASCs and a high frequency of VH4-34 + acN cells, in both cases with strong diseaseassociated autoreactivity. Even more notable for understanding of the selection of SLE autoreactivity, VH4-34 antibodies generated from sequences shared by acN cells and ASCs demonstrated the strong autoreactivity of naive cells without mutation. Published studies have demonstrated substantial polyreactivity of naive B cells to nonspecific antigens (insulin, single-stranded DNA and lipopolysaccharide) 42 and concluded that lupus memory cells with ANA and anti-Ro reactivity require SHM of non-autoreactive B cells in the GC 44 . Thus, we have provided original evidence of naive B cells without mutation that showed strong auto-polyreactivity to several lupus-specific autoantigens, including dsDNA, chromatin and ribosomal P antigens. We also demonstrated that acN B cells were directly selected into the autoimmune effector compartment without the need for affinity maturation. This feature is consistent with extrafollicular generation of lupus autoantibodies, a pathway that, while well defined in mouse models 17, 18 , has remained unexplored in human SLE. The importance of our findings is enhanced by the demonstration of accelerated lupus-like autoimmunity mediated by GC-independent IgM autoantibodies 45 .
Our study indicated very long persistence of peripheral naive B cells and ASCs in SLE. Mature peripheral B cells in rodents have a lifespan of 2-6 weeks, a time frame shortened to just a few days for autoreactive naive B cells 46, 47 . The only in vivo human study available has estimated the half-life of circulating naive cells at 22 d (ref. 48) . We found that naive cells without mutation were present concurrently with clonally related ASCs with mutational loads expected to accumulate over many weeks, according to estimates made for mice of the lpr (lymphoproliferation) strain 24, 26 . Moreover, we were able to readily identify at the single-cell level autoreactive acN cells without mutation 4 months after initial detection by NGS. Such prolonged survival could be explained, at least in part, by the high concentrations of B cell-activation factor characteristic of SLE 49 . Similarly, while normal plasmablasts undergo apoptosis within a few days, the persistence of ASC clones in the circulation for at least 8 weeks would suggest a much longer lifespan in SLE. This is consistent with the prolonged survival of plasmablasts reported in autoimmune mice deficient in the tyrosine kinase Lyn 50 .
In summary, we have demonstrated active SLE characterized by large polyclonal expansions of newly generated ASC populations. These ASC populations, however, also contained substantial clonal expansions of antigen-specific autoreactive cells, of which a sizeable fraction was derived from persistently acN cell and, at least in some cases, without the need for SHM. The aggregate of our results is consistent with a model of sustained and asymmetric differentiation of acN cells 51 through both extrafollicular pathways and GC reactions 18 , a possibility that best explains the composition of genealogical clonal trees observed at a single time point in the blood.
Our study provides an immunological explanation for the clinical benefit of belimumab (antibody to B cell-activation factor) and epratuzumab (anti-CD22), which 'preferentially' affect acN cells 49, 52 . The B cell populations described here represent candidate biomarkers for the analysis of patient disease activity, prediction of flares and design of personalized therapies. At a fundamental level, the study of clonally expanded acN cells and their highly diversified progeny should help elucidate the nature of the potentially distinct antigens that trigger the initial activation and subsequent selection of autoreactive B cells in SLE.
METHODS
Methods and any associated references are available in the online version of the paper. anti-human IgA (5 µg/ml; 62-7400; Invitrogen), Trivalent Influenza Vaccine 2009-2010, 2010-2011 (6 µg/ml; Sanofi Pasteur), or monoclonal antibody 9G4 (provided by F.K. Stevenson). After overnight incubation, wells were washed, and bound antibodies were detected with alkaline phosphataseconjugated antibody to human IgG; (109-055-008), to human IgA (109-055-011) or to human IgM (109-055-129) (all from Jackson Immunoresearch; all used at a concentration of 1 µg/ml) and results were developed with Blue Alkaline Phosphatase Substrate Kit III (Vector Laboratories). Spots in each well were counted with a CTL immunospot reader (Cellular Technologies). Results are represented as the ratio of antigen-specific spots to total IgG spots.
Serum IgG proteomics. Serum proteomics was used for analysis of serum antibodies by nano-flow liquid chromatography coupled to tandem mass spectrometry as described 27 . The 9G4 + antibody fraction was purified from the serum of two of the patients with SLE by affinity chromatography with monoclonal antibody 9G4. 9G4 + fractions were eluted and their expression of 9G4 was verified, followed by digestion with chymotrypsin, pepsin, elastase or trypsin and analysis by liquid chromatography-tandem mass spectrometry. Highconfidence peptide spectral matches of V regions were obtained with SEQUEST against a reference database created by next-generation DNA sequencing of the various B cell subsets from the same patient with the same blood sample.
Recombinant single-cell monoclonal antibodies. Recombinant single-cell monoclonal antibodies were generated and their autoreactivity was analyzed as described 13 by nested RT-PCR analysis of RNA isolated from single cells sorted from the populations of interest into 96-well plates.
Enzyme-linked immunosorbent assay (ELISA). QUANTA Lite ELISA of ANA, dsDNA, chromatin and ribosomal P by (INOVA Diagnostics) and Total Anti-Cardiolipin Screen ELISA (ALPCO Diagnostics) were performed according to the manufacturer's instructions as described 13 .
ANA immunofluorescence. Slides coated with Hep-2 (Nova lite Hep-2; 708101; INOVA Diagnostics) were incubated for 30 min in a moist chamber at ambient temperature with 20 µl purified antibodies at a concentration of 30 µg/ml, then were washed in PBS, and incubated for 30 min with FITC-labeled goat antibody to human IgG (20 µl; 508123; INOVA Diagnostics). ANA-negative control serum and ANA-positive control serum was included in all experiments. Samples were examined on a confocal microscope (Olympus FV1000/TIRF; Emory University Integrated Cellular Imaging Microscopy Core). Positive staining was determined by comparison with the control samples assessed at equal exposure times.
Statistical analysis. Statistical comparisons between groups were performed with a two-sample t-test with unequal variances. In some cases involving comparisons of lineage counts or cases in which we did not assume normally distributed data, we used a Wilcoxon rank sum test. All statistical tests were computed with Matlab (The Mathworks).
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